Diabetic Gastroparesis Drug Pipeline Analysis Report 2025

According to the American Diabetes Association, the prevalence of gastroparesis is approximately 5% in patients with type 1 diabetes and 1% in type 2 diabetes. Gastroparesis is also called delayed gastric emptying, which is a disorder of the digestive tract causing food to remain in the stomach for a longer period than average. Common medications given to manage the disease include antihistamines, and antibiotics among others. Several clinical trials are ongoing to develop innovative diabetic gastroparesis therapeutics to improve and manage the condition including prokinetic agents or antiemetic agents.

Report Coverage

The Diabetic Gastroparesis Pipeline Report by the publisher gives comprehensive insights into diabetic gastroparesis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for diabetic gastroparesis. The diabetic gastroparesis pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies . It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from diabetic gastroparesis.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing diabetic gastroparesis pipeline development activities related to diabetic gastroparesis are covered.

Diabetic Gastroparesis Drug Pipeline Outlook

Diabetic gastroparesis is a digestive condition that affects how the stomach moves food into the intestines and leads to bloating, nausea, and heartburn. Gastroparesis is a disorder characterized by delayed gastric emptying due to damage to the vagus nerve. The disease is more prevalent in patients having type 1 diabetes than type 2 diabetes. It can be a result of long-term high blood sugar levels which damage the nerves responsible for stomach function. The disease is more common in females than males and is more likely to develop in people who have had surgery around the esophagus, small intestine, or stomach. Moreover, people who have had radiation therapy around the stomach or chest areas are more likely to develop gastroparesis. The symptoms of diabetic gastroparesis include vomiting, nausea, abdominal pain, acid reflux, abdominal bloating, and lack of appetite among others.

The treatment for diabetic gastroparesis varies and includes changing the dosage and timing of insulin, oral diabetic gastroparesis therapeutic drugs such as metoclopramide or erythromycin which stimulate the stomach muscles and avoiding drugs that cause delayed gastric emptying among others. Clinical trials for diabetic gastroparesis are focusing on several aspects including new diabetic gastroparesis drug candidates, such as the developments of prokinetic agents or antiemetic agents, and combinational therapies. Currently, a clinical trial is investigating the use of oral cannabidiol in the treatment of gastroparesis. The results reported improvement in symptoms as well. The increased number of drug clinical trials for diabetic gastroparesis has impacted the pipeline landscape significantly.

Diabetic Gastroparesis - Drug Pipeline Therapeutic Assessment

This section of the diabetic gastroparesis report covers the analysis of diabetic gastroparesis drugs based on several segmentations including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase.

Late-Stage Products (Phase 3 and Phase 4)
Mid-Stage Products (Phase 2)
Early-Stage Products (Phase I)
Preclinical and Discovery Stage Products

By Drug Class

The diabetic gastroparesis therapeutic assessment covers 50+ drug analyses based on drug classes:

Monoclonal Antibody
Peptides
Polymer
Small Molecule
Gene Therapy

By Route of Administration

The diabetic gastroparesis clinical assessment covers 50+ drug analyses based on the route of administration.

Oral
Parenteral
Others

Diabetic Gastroparesis - Pipeline Assessment Segmentation, By Phases

The diabetic gastroparesis report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for diabetic gastroparesis with 32 pipeline drugs in phase II.

Diabetic Gastroparesis - Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under diabetic gastroparesis pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. Vanda Pharmaceuticals announced that the US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for a neurokinin 1 receptor (NK-1R) antagonist in development for the treatment of gastroparesis. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for diabetic gastroparesis.

Diabetic Gastroparesis Clinical Trials Assessment - Competitive Dynamics

The diabetic gastroparesis report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in diabetic gastroparesis clinical trials:

Vanda Pharmaceuticals
CinDome Pharma, Inc.
Evoke Pharma
Tranzyme, Inc.
Bird Rock Bio, Inc.
Liangzhou Wei
Ironwood Pharmaceuticals, Inc.
Neurogastrx, Inc.
Millennium Pharmaceuticals, Inc.
UCB Pharma
PTC Therapeutics
Others

Diabetic Gastroparesis - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and diabetic gastroparesis therapeutic drugs. It covers necessary details such as product description, study type, drug class, mode of administration, and recruitment status of upcoming diabetic gastroparesis drug candidates.

Drug- CIN-102

The trial is designed to evaluate whether CIN-102 (deudomperidone) can help reduce the symptoms of diabetic gastroparesis in adult patients. The trial is sponsored by CinDome Pharma, Inc. and is currently under phase II.

Drug: Metoclopramide Nasal Spray

The objective of the study is to evaluate the clinical safety and effectiveness of diabetic gastroparesis drug candidate Metoclopramide Nasal Spray compared to placebo for reducing the symptoms associated with diabetic gastroparesis in adult women. The trial is sponsored by Evoke Pharma and is currently under phase III.

Drug: Tradipitant

Vanda Pharmaceuticals is developing the drug and is currently under phase III. The study is being conducted to evaluate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms associated with gastroparesis.

Reasons To Buy This Report

The Diabetic Gastroparesis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for diabetic gastroparesis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into diabetic gastroparesis treatment market trends, regulatory environments, and potential growth opportunities within diabetic gastroparesis pipeline insights.

Key Questions Answered in the Diabetic Gastroparesis - Pipeline Assessment Report

What is the current landscape of diabetic gastroparesis pipeline drugs?
Which companies/institutions are developing diabetic gastroparesis emerging drugs?
How many phase II drugs are currently present in diabetic gastroparesis pipeline drugs?
Which company is leading the diabetic gastroparesis pipeline development activities?
What is the current diabetic gastroparesis clinical assessment?
What are the opportunities and challenges present in the diabetic gastroparesis drug pipeline landscape?
What is the efficacy and safety profile of diabetic gastroparesis pipeline drugs?
Which companies/institutions are involved in diabetic gastroparesis collaborations aimed at providing enhanced therapeutic alternatives for patients?
What are the geographies covered for clinical trials in diabetic gastroparesis?

Related Reports

Global Diabetic Gastroparesis Treatment Market

Global Gastrointestinal Stromal Tumour Treatment Market

Global Gastric Ulcer Treatment Market

This product will be delivered within 3-5 business days.

1 Preface

1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions

2 Executive Summary

3 Overview of Diabetic Gastroparesis

3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment

4 Patient Profile: Diabetic Gastroparesis

4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate

5 Diabetic Gastroparesis: Epidemiology Snapshot

5.1 Diabetic Gastroparesis Incidence by Key Markets
5.2 Diabetic Gastroparesis- Patients Seeking Treatment in Key Markets

6 Diabetic Gastroparesis: Market Dynamics

6.1 Market Drivers and Constraints
6.2 SWOT Analysis

7 Diabetic Gastroparesis: Key Facts Covered

7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions

8 Diabetic Gastroparesis, Drug Pipeline Assessment

8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class

9 Drug Pipeline Comparative Analysis

9.1 List of Diabetic Gastroparesis Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)

10 Diabetic Gastroparesis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)

10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Metoclopramide Nasal Spray
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Tradipitant
10.2.3 Mosapride
10.2.4 Other Drugs

11 Diabetic Gastroparesis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)

11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Nimacimab
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 NG101
11.2.3 Other Drugs

12 Diabetic Gastroparesis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)

12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 TC-6499
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Lixisenatide
12.2.3 Other Drugs

13 Diabetic Gastroparesis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)

13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs

14 Diabetic Gastroparesis, Key Drug Pipeline Companies

14.1 Vanda Pharmaceuticals
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 CinDome Pharma, Inc.
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Evoke Pharma
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Tranzyme, Inc.
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Bird Rock Bio, Inc.
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Liangzhou Wei
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Ironwood Pharmaceuticals, Inc.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 Neurogastrx, Inc.
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
14.9 Millennium Pharmaceuticals, Inc.
14.9.1 Company Snapshot
14.9.2 Pipeline Product Portfolio
14.9.3 Financial Analysis
14.9.4 Recent News and Developments
14.10 UCB Pharma
14.10.1 Company Snapshot
14.10.2 Pipeline Product Portfolio
14.10.3 Financial Analysis
14.10.4 Recent News and Developments
14.11 PTC Therapeutics
14.11.1 Company Snapshot
14.11.2 Pipeline Product Portfolio
14.11.3 Financial Analysis
14.11.4 Recent News and Developments

15 Regulatory Framework for Drug Approval, By Region16 Terminated or Suspended Pipeline Products

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2452EUR$2,789USD£2,113GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€3437EUR$3,909USD£2,961GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€4483EUR$5,099USD£3,863GBP